Business, energy, technology, markets and global industry news from Business News Today

Pharma & Biotech

PharmaDeviceNews Pharma & Biotech
AusperBio’s AHB-171 clinical study marks the first patient dosing of its investigational liver-targeted siRNA candidate for chronic hepatitis B, expanding the company’s pursuit of a functional HBV cure. Representative image.
Pharma & Biotech

AusperBio has entered the HBV siRNA race, but can AHB-171 move beyond antigen suppression?

AusperBio has dosed the first patient with AHB-171, testing a liver-targeted siRNA candidate and a broader combination strategy for hepatitis B.

Read More
A patient receives hospital-based infusion therapy as Australia’s PBS listing of Minjuvi expands access to a chemotherapy-free immunotherapy combination for adults with relapsed or refractory follicular lymphoma. Representative image.
Pharma & Biotech

Incyte’s Minjuvi gains Australian reimbursement after TGA follicular lymphoma registration

Australia has listed Minjuvi on the PBS for relapsed follicular lymphoma. See what the inMIND data and access terms mean.

Read More
Mezzion’s investigational drug udenafil has reduced kidney cyst burden in an ADPKD animal study, strengthening the scientific rationale for the company’s planned Phase 2b clinical programme. Representative image.
Pharma & Biotech

Mezzion’s new kidney disease data sent shares higher, but the decisive test is still ahead

Mezzion reports animal-model ADPKD data for udenafil as it prepares Phase 2b testing. The findings support development, but human efficacy is unproven.

Read More
GlycoNex has dosed the first patient in a Phase I trial of GNX1021, beginning the clinical evaluation of its glycan-directed antibody-drug conjugate in advanced gastrointestinal cancers. Representative image.
Pharma & Biotech

GlycoNex has taken GNX1021 into humans, but its bold glycan-targeting theory now faces the real test

GlycoNex has dosed the first patient in a multinational Phase I trial of GNX1021, moving its lead glycan-directed antibody-drug conjugate from laboratory studies into human testing. The milestone begins a far more consequential phase in which investigators must establish whether targeting branched Lewis B/Y can produce a usable therapeutic window in advanced gastrointestinal cancers.

Read More
An acute myeloid leukemia research setting illustrates Moleculin Biotech’s Annamycin trial and its 37% blinded remission signal in resistant AML after venetoclax treatment. Representative image.
Pharma & Biotech

Moleculin reports 37% blinded remission rate as Annamycin AML trial nears critical readout

Moleculin Biotech has reported a preliminary 37% composite complete remission rate among 62 evaluable patients in Part A of its pivotal Phase 2/3 MIRACLE trial of Annamycin plus cytarabine for relapsed or refractory acute myeloid leukemia. The July 31 update also showed a 24% complete remission rate across the blinded study population. Among 30 evaluable

Read More
Pfizer’s positive Phase 3 LITFULO results in nonsegmental vitiligo have strengthened the treatment’s global regulatory prospects, while detailed efficacy, safety and durability data remain key to its clinical and commercial outlook. Representative image.
Pharma & Biotech

Pfizer’s LITFULO cleared a major Phase 3 hurdle in vitiligo, but the missing numbers could decide its future

Pfizer’s Phase 3 LITFULO vitiligo results strengthen its filing case, but dose, safety and durability details remain decisive.

Read More
Verdiva Bio has begun Phase 1 testing of VRB-103, an investigational oral amylin peptide analog designed to evaluate the potential for once-weekly obesity treatment. Representative image.
Pharma & Biotech

Can a weekly obesity pill move beyond GLP-1? Verdiva Bio puts oral amylin candidate VRB-103 into human testing

Verdiva Bio has begun Phase 1 testing of weekly oral amylin candidate VRB-103. See what the trial can prove and what remains uncertain.

Read More
Evommune’s investigational oral MRGPRX2 inhibitor EVO756 enters a Phase 2b migraine prevention trial, testing a new neuroimmune approach after the programme’s urticaria setback. Representative image.
Pharma & Biotech

Can MRGPRX2 inhibition prevent migraine? Evommune’s EVO756 enters Phase 2b study

Evommune begins a Phase 2b EVO756 migraine trial after a urticaria setback, testing whether MRGPRX2 inhibition can deliver preventive benefit.

Read More
Eli Lilly strengthens domestic medicine supply through Resilience manufacturing deal
Pharma & Biotech

What the $750m Eli Lilly and Resilience investment means for medicine supply

Eli Lilly and Resilience are investing $750 million to expand U.S. KwikPen production in Ohio. See why manufacturing execution now matters.

Read More
Sumitomo Pharma’s investigational menin inhibitor enzomenib gains FDA orphan drug designation as development advances for acute lymphoblastic leukemia. Representative image.
Pharma & Biotech

Sumitomo Pharma’s enzomenib receives FDA orphan drug designation for acute lymphoblastic leukemia

FDA orphan drug status expands enzomenib’s ALL pathway as Sumitomo Pharma advances pivotal development in biomarker-defined acute leukemia.

Read More